TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection
Clinical trial NCT05111366 · UNKNOWN
Trial details
- NCT number
- NCT05111366
- Sponsor
- Xianhai Mao
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-06
- Primary completion
- 2024-01-20
- Enrollment
- 37
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.